Q&A: Liraglutide outperforms colesevelam in reducing stool frequency in bile acid diarrhea

Liraglutide reduced stool frequency in a small subset of patients with bile acid diarrhea and warrants consideration as a potential new treatment modality, according to research in The Lancet Gastroenterology and Hepatology.Researchers aimed to investigate the safety and efficacy of liraglutide, a glucagon-like peptide 1 receptor agonist, in patients with bile acid diarrhea, which is often underdiagnosed and estimated to affect 1% to 2% of the general population.In a double-blind clinical trial in Denmark, 52 patients (mean age, 50.2 years) with verified bile acid diarrhea received either oneRead More

Related Articles